Key result
In 866 subjects followed for up to 9 years, baseline Lgals3bp levels above the median were associated with incident diabetes, metabolic syndrome, chronic liver diseases, and high multimorbidity.
Why the study?
Are higher serum levels of Galectin-3-binding protein associated with adverse metabolic and inflammatory profiles over time in a general population?
Cohort (n=866)
Yes
Are higher serum levels of Galectin-3-binding protein associated with adverse metabolic and inflammatory profiles over time in a general population?
Answers are grounded in this paper and cite their sources.
Elevated Lgals3bp levels are a potential biomarker for incident diabetes, metabolic syndrome, and chronic low-grade inflammation.
Galectin-3-binding protein (Lgals3bp), a heavily glycosylated protein that plays a role in cell growth, inflammation, and cellular adhesion, has been associated with tumor development and more recently with carbohydrate and lipid metabolism. The primary aims of these analyses are to examine in the InCHIANTI study participants: 1) the cross-sectional correlations of Lgals3bp serum levels with biomarkers of inflammation, glucose, and cholesterol metabolism; 2) the longitudinal association between baseline Lgals3bp serum levels with changes over time of inflammatory markers, blood glucose, and cholesterol. The InCHIANTI study enrolled representative samples from the registry lists of two towns in Tuscany, Italy. Baseline data were collected in 1998, with follow up visits every three years up to nine years. For this analysis, we used 866 subjects whose variables of interest had been recorded. Subjects were divided in two groups according to Lgals3bp levels, above median AM-Lgals3bp and below median BM-Lgals3bp. In cross-sectional analyses higher blood glucose, plasma insulin, elevated leptin, lower LDL-cholesterol, and inflammatory makers were associated to AM-Lgals3bp levels. Longitudinally, baseline AM-Lgals3bp levels were associated with incident diabetes, MetS, chronic liver diseases, and high multimorbidity score. Lastly AM-Lgals3bp levels predicted high blood-glucose, and high HS-C-Reactive-protein, and low HDL-cholesterol throughout the time of the study. These results point to the role of Lgals3bp in affecting low-grade age-related inflammation, low circulating cholesterol levels, and diabetes. Therefore, Lgals3bp could be further evaluated for diagnostic and therapeutic purposes.
No takes yet. Share an insight, caveat, or question.
Pellegrino et al. (2025) conducted a cohort in Diabetes, metabolic syndrome, and inflammation (n=866). Above median Galectin-3-binding protein (AM-Lgals3bp) vs. Below median Galectin-3-binding protein (BM-Lgals3bp) was evaluated on Incident diabetes, metabolic syndrome, chronic liver diseases, and high multimorbidity score. In 866 subjects followed for up to 9 years, baseline Lgals3bp levels above the median were associated with incident diabetes, metabolic syndrome, chronic liver diseases, and high multimorbidity.
Synapse has enriched 10 related papers. Consider them for comparative context: